Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis
Retrospective analysis reveals comparable outcomes for CAR-T therapy in elderly patients and younger counterparts, highlighting the need for a broader age inclusion criterion.
Key Points
Elderly patients receiving CAR-T therapy exhibited similar overall survival and toxicity outcomes as younger adults.
Following propensity score matching, 112 patients per age cohort were analyzed to assess the outcomes.
Real-world data indicates hospitalization rates among older patients are not significantly higher than younger individuals.
Results emphasize that age alone should not dictate eligibility for CAR-T therapy in cancer treatment.